Company / Cash & Equivalents
Intellia Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$155.5M
FY2025
5-year range
$123.4M / $523.5M
FY2021-FY2025
Trend
-17.8%
vs FY2024
Sector context
#98 of 152
Health Care
What the data says
At $155M, Intellia Therapeutics, Inc.'s cash & equivalents ranks #98 of 152 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $524M in FY2022 to $155M in FY2025.
Based on SEC 10-K filings.
$155M in FY2025 with a 5-year CAGR of -0.6%.
Declined from $227M to $155M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -33.3%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
#98 of 152 in Health CareTop 64% of 152This company $155.5M Sector average $1.2B
▼
-86.6% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 17.8% year-over-year.
- Ranks #98 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $155.5M | -17.8% |
| FY2024 | $189.2M | -16.6% |
| FY2023 | $226.7M | -56.7% |
| FY2022 | $523.5M | +324.2% |
| FY2021 | $123.4M | -22.9% |
| FY2020 | $160.0M | +179.6% |
| FY2019 | $57.2M | -2.8% |
| FY2018 | $58.9M | -82.7% |
| FY2017 | $340.7M | +24.8% |
| FY2016 | $273.1M | +260.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026